How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

165 results for

Primary Idiopathic Polymyositis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Primary Idiopathic Polymyositis

Primary Idiopathic Polymyositis Primary Idiopathic Polymyositis Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Primary Idiopathic (...) Polymyositis Primary Idiopathic Polymyositis Aka: Primary Idiopathic Polymyositis From Related Chapters II. Pathophysiology Group I of disorders (accounts for 33%) III. Epidemiology higher in women by ratio of 2:1 IV. Course Insidiously progressive over weeks to years V. Symptoms: Proximal limb weakness Hip and weakness (Most significant) Difficult rising from seated/kneeling position Difficult climbing/descending stairs Unable to walk (5%) Shoulder Difficulty reaching overhead (e.g. combing hair) Buttock

2018 FP Notebook

2. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. (PubMed)

Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Idiopathic inflammatory myopathies are chronic diseases with significant mortality and morbidity. Whilst immunosuppressive and immunomodulatory therapies are frequently used, the optimal therapeutic regimen remains unclear. This is an update of a review first published in 2005.To assess the effects of immunosuppressants and immunomodulatory treatments for dermatomyositis and polymyositis.We searched (...) the Cochrane Neuromuscular Disease Group Specialized Register (August 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3 2011), MEDLINE (January 1966 to August 2011), EMBASE (January 1980 to August 2011) and clinicaltrials.gov (August 2011). We checked the bibliographies of identified trials and wrote to disease experts.We included all randomised controlled trials (RCTs) or quasi-RCTs involving participants with probable or definite dermatomyositis and polymyositis as defined

2012 Cochrane

3. Diagnosis of Idiopathic Pulmonary Fibrosis

Diagnosis of Idiopathic Pulmonary Fibrosis AMERICANTHORACICSOCIETY DOCUMENTS DiagnosisofIdiopathic PulmonaryFibrosis An Of?cial ATS/ERS/JRS/ALAT Clinical Practice Guideline Ganesh Raghu, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morell, Kevin R. Flaherty, Athol Wells, Fernando J. Martinez, Arata Azuma, Thomas J. Bice, Demosthenes Bouros, Kevin K. Brown, Harold R. Collard, Abhijit Duggal (...) BAL.Additionalrecommendationsincludedaconditional recommendationformultidisciplinarydiscussionandastrong recommendationagainstmeasurementofserumbiomarkersfor thesolepurposeofdistinguishingIPFfromotherILDs. Conclusions:Theguidelinepanelprovidedrecommendations relatedtothediagnosisofIPF. Keywords: idiopathic pulmonary ?brosis; interstitial lung disease; pulmonary ?brosis An Executive Summary of this document is available at http://www.atsjournals.org/doi/suppl/10.1164/rccm.201807-1255ST. ORCID IDs: 0000-0001-7506-6643 (G.R.); 0000-0001-8247

2018 American Thoracic Society

4. Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis

Assessor) Primary Purpose: Treatment Official Title: Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis Actual Study Start Date : January 2017 Estimated Primary Completion Date : January 2020 Estimated Study Completion Date : January 2020 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Exposed Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks (...) Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lipid-lowering

2017 Clinical Trials

5. Primary Idiopathic Polymyositis

Primary Idiopathic Polymyositis Primary Idiopathic Polymyositis Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Primary Idiopathic (...) Polymyositis Primary Idiopathic Polymyositis Aka: Primary Idiopathic Polymyositis From Related Chapters II. Pathophysiology Group I of disorders (accounts for 33%) III. Epidemiology higher in women by ratio of 2:1 IV. Course Insidiously progressive over weeks to years V. Symptoms: Proximal limb weakness Hip and weakness (Most significant) Difficult rising from seated/kneeling position Difficult climbing/descending stairs Unable to walk (5%) Shoulder Difficulty reaching overhead (e.g. combing hair) Buttock

2015 FP Notebook

6. Polymyositis

(NCI_NCI-GLOSS) An inflammatory disease of the muscles closest to the center of the body. It causes weakness, inability to stand, climb stairs, lift, or reach. It may also cause muscle pain and difficulty swallowing, and may affect the lungs and heart. Having polymyositis increases the risk of certain types of cancer. Definition (NCI) An idiopathic inflammatory disorder affecting the muscles. It presents with symmetrical proximal muscle weakness and elevated skeletal muscle enzymes. Definition (CSP (...) , Zapalenie wielomięśniowe Hungarian Polymyositis Norwegian Polymyositt Dutch polymyositis , Myositis, multipele , Polymyositis Italian Polimiosite Derived from the NIH UMLS ( ) Related Topics in Connective Tissue Disorders About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 interlinked topic pages divided into a tree of 31 specialty books and 728 chapters. Content is with systematic

2018 FP Notebook

7. WITHDRAWN: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. (PubMed)

WITHDRAWN: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Idiopathic inflammatory myopathies are chronic skeletal diseases with significant mortality and morbidity despite treatment by corticosteroids. Immunosuppressive agents and immunomodulatory therapy are used to improve disease control and reduce the long-term side effects of corticosteroids. While these treatments are used commonly in routine clinical practice, the optimal therapeutic regimen (...) dermatomyositis and polymyositis as defined by the criteria of Bohan and Peter or definite, probable or mild/early by the criteria of Dalakas. Patients with inclusion body myositis should have been excluded by muscle biopsies. Any immunosuppressant or immunomodulatory treatment including corticosteroids, azathioprine, methotrexate, ciclosporin, chlorambucil, cyclophosphamide, intravenous immunoglobulin, interferon and plasma exchange was considered. Primary outcome was assessment of muscle strength after

2009 Cochrane

8. An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis (SPIRIT)

Recruitment Status : Recruiting First Posted : June 29, 2018 Last Update Posted : March 20, 2019 See Sponsor: Biogen Information provided by (Responsible Party): Biogen Study Details Study Description Go to Brief Summary: The primary objective of this study is to evaluate the efficacy of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). The secondary objectives of this study are: to evaluate the efficacy of BG00011 compared with placebo in participants with IPF (...) . Condition or disease Intervention/treatment Phase Idiopathic Pulmonary Fibrosis Drug: BG00011 Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 290 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate

2018 Clinical Trials

9. A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

consecutive days of each 7 day "on" week. Condition or disease Intervention/treatment Phase Idiopathic Pulmonary Fibrosis Drug: SM04646 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 0 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase 2a, 24-Week, Multi-Center, Open-Label Study Evaluating the Safety, Pharmacokinetics (...) , Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Estimated Study Start Date : January 1900 Estimated Primary Completion Date : January 1900 Estimated Study Completion Date : January 1900 Resource links provided by the National Library of Medicine related topics: related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: "BAL" Arm Subjects in this arm will undergo a bronchoalveolar lavage (BAL) procedure

2018 Clinical Trials

10. Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).

Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 60 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice Actual Study Start Date : October 23, 2017 Estimated Primary Completion Date : June 24 (...) Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

11. Optimizing Treatment on Idiopathic Inflammatory Myopathies

Detailed Description: To compare two groups of patients as described in Brief Summary. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 60 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Optimizing Treatment on Idiopathic Inflammatory Myopathies Study Start Date : January 2005 Estimated Primary Completion Date : January 2019 Estimated Study Completion Date : January 2026 Resource links provided by the National (...) Optimizing Treatment on Idiopathic Inflammatory Myopathies Optimizing Treatment on Idiopathic Inflammatory Myopathies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Optimizing Treatment on Idiopathic

2017 Clinical Trials

12. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis

2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis ARTHRITIS & RHEUMATISM Vol. 65, No. 10, October 2013, pp 2499–2512 DOI 10.1002/art.38092 © 2013, American College of Rheumatology SPECIAL ARTICLE 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis (...) ), who also reviewed each article’s final determination. A total of 125 articles were included in the final Evidence Report. Three articles were subsequently included from the updated literature search. The data abstracted from each article for the Evidence Report included study design, participants (number and diagnosis), medication (including dose), concurrent medications, inclusion criteria, exclusion cri- teria, baseline disease measures, primary and secondary out- comes, adverse events

2013 American College of Rheumatology

13. Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

adult PM and DM as well as supporting its role from animal models and human studies. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Official Title: Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Actual Study Start Date : October 1 (...) Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2014 Clinical Trials

14. Dermatomyositis/Polymyositis (Diagnosis)

in older men. Bohan and Peter classified the idiopathic inflammatory myopathies as follows [ ] : I - Primary idiopathic polymyositis II - Primary idiopathic dermatomyositis III - Polymyositis or dermatomyositis associated with malignancy [ ] IV - Childhood polymyositis or dermatomyositis V - Polymyositis or dermatomyositis associated with another connective-tissue disease VI - Inclusion body myositis VII - Miscellaneous (eg, eosinophilic myositis, myositis ossificans, focal myositis, giant cell (...) , 2018 Author: Mythili Seetharaman, MD; Chief Editor: Herbert S Diamond, MD Share Email Print Feedback Close Sections Sections Polymyositis Overview Practice Essentials Polymyositis is an idiopathic inflammatory myopathy characterized by the following [ ] : Symmetrical, proximal muscle weakness Elevated skeletal muscle enzyme levels Characteristic electromyography (EMG) and muscle biopsy findings (see the images below). MRI of thighs showing increased signal in the quadriceps muscles bilaterally

2014 eMedicine.com

15. Polymyositis (Overview)

and Peter classified the idiopathic inflammatory myopathies as follows [ ] : I - Primary idiopathic polymyositis II - Primary idiopathic dermatomyositis III - Polymyositis or dermatomyositis associated with malignancy [ ] IV - Childhood polymyositis or dermatomyositis V - Polymyositis or dermatomyositis associated with another connective-tissue disease VI - Inclusion body myositis VII - Miscellaneous (eg, eosinophilic myositis, myositis ossificans, focal myositis, giant cell myositis) Necrotizing (...) Seetharaman, MD; Chief Editor: Herbert S Diamond, MD Share Email Print Feedback Close Sections Sections Polymyositis Overview Practice Essentials Polymyositis is an idiopathic inflammatory myopathy characterized by the following [ ] : Symmetrical, proximal muscle weakness Elevated skeletal muscle enzyme levels Characteristic electromyography (EMG) and muscle biopsy findings (see the images below). MRI of thighs showing increased signal in the quadriceps muscles bilaterally consistent with inflammatory

2014 eMedicine.com

16. Polymyositis (Treatment)

supplementation and oral bisphosphonates for osteoporosis prophylaxis or other agents for osteoporosis treatment. Previous References Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun . 2014 Feb-Mar. 48-49:118-21. . Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Front Neurol . 2016 May 20. 7:64. . Na SJ, Kim SM, Sunwoo IN, Choi YC. Clinical characteristics and outcomes of juvenile and adult (...) dermatomyositis. J Korean Med Sci . 2009 Aug. 24(4):715-21. . . Bohan A. History and classification of polymyositis and dermatomyositis. Clin Dermatol . 1988 Apr-Jun. 6(2):3-8. . Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev . 2010 Apr. 9(6):449-53. . Carroll MB, Newkirk MR, Sumner NS. Necrotizing Autoimmune Myopathy: A Unique Subset of Idiopathic Inflammatory Myopathy. J Clin Rheumatol . 2016 Oct. 22 (7):376-80. . Lee CW, Muo CH

2014 eMedicine.com

17. Dermatomyositis/Polymyositis (Overview)

. Bohan and Peter classified the idiopathic inflammatory myopathies as follows [ ] : I - Primary idiopathic polymyositis II - Primary idiopathic dermatomyositis III - Polymyositis or dermatomyositis associated with malignancy [ ] IV - Childhood polymyositis or dermatomyositis V - Polymyositis or dermatomyositis associated with another connective-tissue disease VI - Inclusion body myositis VII - Miscellaneous (eg, eosinophilic myositis, myositis ossificans, focal myositis, giant cell myositis (...) Author: Mythili Seetharaman, MD; Chief Editor: Herbert S Diamond, MD Share Email Print Feedback Close Sections Sections Polymyositis Overview Practice Essentials Polymyositis is an idiopathic inflammatory myopathy characterized by the following [ ] : Symmetrical, proximal muscle weakness Elevated skeletal muscle enzyme levels Characteristic electromyography (EMG) and muscle biopsy findings (see the images below). MRI of thighs showing increased signal in the quadriceps muscles bilaterally consistent

2014 eMedicine.com

18. Dermatomyositis/Polymyositis (Treatment)

supplementation and oral bisphosphonates for osteoporosis prophylaxis or other agents for osteoporosis treatment. Previous References Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun . 2014 Feb-Mar. 48-49:118-21. . Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Front Neurol . 2016 May 20. 7:64. . Na SJ, Kim SM, Sunwoo IN, Choi YC. Clinical characteristics and outcomes of juvenile and adult (...) dermatomyositis. J Korean Med Sci . 2009 Aug. 24(4):715-21. . . Bohan A. History and classification of polymyositis and dermatomyositis. Clin Dermatol . 1988 Apr-Jun. 6(2):3-8. . Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev . 2010 Apr. 9(6):449-53. . Carroll MB, Newkirk MR, Sumner NS. Necrotizing Autoimmune Myopathy: A Unique Subset of Idiopathic Inflammatory Myopathy. J Clin Rheumatol . 2016 Oct. 22 (7):376-80. . Lee CW, Muo CH

2014 eMedicine.com

19. Polymyositis (Follow-up)

supplementation and oral bisphosphonates for osteoporosis prophylaxis or other agents for osteoporosis treatment. Previous References Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun . 2014 Feb-Mar. 48-49:118-21. . Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Front Neurol . 2016 May 20. 7:64. . Na SJ, Kim SM, Sunwoo IN, Choi YC. Clinical characteristics and outcomes of juvenile and adult (...) dermatomyositis. J Korean Med Sci . 2009 Aug. 24(4):715-21. . . Bohan A. History and classification of polymyositis and dermatomyositis. Clin Dermatol . 1988 Apr-Jun. 6(2):3-8. . Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev . 2010 Apr. 9(6):449-53. . Carroll MB, Newkirk MR, Sumner NS. Necrotizing Autoimmune Myopathy: A Unique Subset of Idiopathic Inflammatory Myopathy. J Clin Rheumatol . 2016 Oct. 22 (7):376-80. . Lee CW, Muo CH

2014 eMedicine.com

20. Dermatomyositis/Polymyositis (Follow-up)

supplementation and oral bisphosphonates for osteoporosis prophylaxis or other agents for osteoporosis treatment. Previous References Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun . 2014 Feb-Mar. 48-49:118-21. . Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Front Neurol . 2016 May 20. 7:64. . Na SJ, Kim SM, Sunwoo IN, Choi YC. Clinical characteristics and outcomes of juvenile and adult (...) dermatomyositis. J Korean Med Sci . 2009 Aug. 24(4):715-21. . . Bohan A. History and classification of polymyositis and dermatomyositis. Clin Dermatol . 1988 Apr-Jun. 6(2):3-8. . Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev . 2010 Apr. 9(6):449-53. . Carroll MB, Newkirk MR, Sumner NS. Necrotizing Autoimmune Myopathy: A Unique Subset of Idiopathic Inflammatory Myopathy. J Clin Rheumatol . 2016 Oct. 22 (7):376-80. . Lee CW, Muo CH

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>